Per-Anders Broliden

715 total citations
7 papers, 559 citations indexed

About

Per-Anders Broliden is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Per-Anders Broliden has authored 7 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Virology, 3 papers in Infectious Diseases and 3 papers in Immunology. Recurrent topics in Per-Anders Broliden's work include HIV Research and Treatment (6 papers), T-cell and Retrovirus Studies (2 papers) and HIV/AIDS drug development and treatment (2 papers). Per-Anders Broliden is often cited by papers focused on HIV Research and Treatment (6 papers), T-cell and Retrovirus Studies (2 papers) and HIV/AIDS drug development and treatment (2 papers). Per-Anders Broliden collaborates with scholars based in Sweden, United States and Cuba. Per-Anders Broliden's co-authors include Viktoria Hjalmar, G Hale, Anders Österborg, Jeanette Lundin, Magnus Björkholm, Lars Möllgård, Eva Kimby, Håkan Mellstedt, Herman Waldmann and Fredrik Celsing and has published in prestigious journals such as Blood, AIDS and AIDS Research and Human Retroviruses.

In The Last Decade

Per-Anders Broliden

7 papers receiving 544 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Per-Anders Broliden Sweden	6	254	247	226	162	143	7	559
R Sancetta Italy	15	515 2.0×	176 0.7×	163 0.7×	77 0.5×	30 0.2×	22	781
GS Wood United States	9	210 0.8×	102 0.4×	237 1.0×	36 0.2×	110 0.8×	15	487
Shigehisa Mori Japan	13	105 0.4×	84 0.3×	111 0.5×	94 0.6×	34 0.2×	40	625
Gemma Pidelaserra-Martí Germany	6	349 1.4×	88 0.4×	89 0.4×	30 0.2×	149 1.0×	7	630
C. Moroz Israel	11	164 0.6×	68 0.3×	45 0.2×	52 0.3×	42 0.3×	47	541
Mark Duval United States	14	231 0.9×	41 0.2×	46 0.2×	250 1.5×	177 1.2×	25	465
Knowles Dm United States	9	182 0.7×	123 0.5×	309 1.4×	17 0.1×	50 0.3×	9	468
Alessandra Sottini Italy	11	498 2.0×	31 0.1×	74 0.3×	155 1.0×	32 0.2×	17	675
DT Scadden United States	10	316 1.2×	101 0.4×	88 0.4×	203 1.3×	12 0.1×	18	814
Lindi Tan United States	8	163 0.6×	69 0.3×	77 0.3×	242 1.5×	14 0.1×	8	578

Countries citing papers authored by Per-Anders Broliden

Since Specialization

Citations

This map shows the geographic impact of Per-Anders Broliden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per-Anders Broliden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per-Anders Broliden more than expected).

Fields of papers citing papers by Per-Anders Broliden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per-Anders Broliden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per-Anders Broliden. The network helps show where Per-Anders Broliden may publish in the future.

Co-authorship network of co-authors of Per-Anders Broliden

This figure shows the co-authorship network connecting the top 25 collaborators of Per-Anders Broliden. A scholar is included among the top collaborators of Per-Anders Broliden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per-Anders Broliden. Per-Anders Broliden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Lundin, Jeanette, Eva Kimby, Magnus Björkholm, et al.. (2002). Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 100(3). 768–773. 378 indexed citations

2.

Ugen, Kenneth E., Srisakul Kliks, Kristina Broliden, et al.. (1996). A Human Monoclonal Antibody to HIV-1 gp41 with Neutralizing Activity Against Diverse Laboratory Isolates. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 12(3). 221–232. 36 indexed citations

3.

Broliden, Kristina, Jorma Hinkula, Göran Bratt, et al.. (1996). Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160. Clinical and Diagnostic Virology. 6(2-3). 115–126. 5 indexed citations

4.

Duarte, Carlos A., Jorma Hinkula, Per-Anders Broliden, et al.. (1991). Monoclonal Antibodies to Conserved Regions of the Major Core Protein ( gag 24) of HIV-1 and HIV-2. AIDS Research and Human Retroviruses. 7(1). 97–101. 10 indexed citations

5.

Albert, Jan, Anders Nauclér, Blenda Böttiger, et al.. (1990). Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS. 4(4). 291–296. 40 indexed citations

6.

Åkerblom, Lennart, Jorma Hinkula, Per-Anders Broliden, et al.. (1990). Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp 120. AIDS. 4(10). 953–960. 83 indexed citations

7.

Ljunggren, K, Francesca Chiodi, Per-Anders Broliden, et al.. (1989). HIV-1-Specific Antibodies in Cerebrospinal Fluid Mediate Cellular Cytotoxicity and Neutralization. AIDS Research and Human Retroviruses. 5(6). 629–638. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact